| (19) |
 |
|
(11) |
EP 1 743 642 A8 |
| (12) |
CORRECTED EUROPEAN PATENT APPLICATION |
|
Note: Bibliography reflects the latest situation |
| (15) |
Correction information: |
|
Corrected version no 1 (W1 A1) |
| (48) |
Corrigendum issued on: |
|
25.04.2007 Bulletin 2007/17 |
| (43) |
Date of publication: |
|
17.01.2007 Bulletin 2007/03 |
| (22) |
Date of filing: 15.07.2005 |
|
| (51) |
International Patent Classification (IPC):
|
|
| (84) |
Designated Contracting States: |
|
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE
SI SK TR |
|
Designated Extension States: |
|
AL BA HR MK YU |
| (71) |
Applicant: LABORATORIOS DEL DR. ESTEVE, S.A. |
|
08041 Barcelona (ES) |
|
| (72) |
Inventor: |
|
- Buschmann, Helmut Heinrich
08960 Sant Just Desvern (Barcelona) (ES)
|
|
| |
|
| (54) |
Use of substituted pyrazoline compounds and their derivatives for the treatment of
cannabinoid system-associated diseases |
(57) The present invention relates to the use of substituted pyrazoline compounds, their
derivatives as well as their physiologically acceptable salts , in medicinal products
for human therapeutics and/or animal research for the treatment of a variety of diseases
associated the cannabinoid receptor system in humans and animals.